海利生物(603718) - 2019 Q1 - 季度财报

Financial Performance - Operating revenue for the first quarter reached CNY 80,956,247.28, a 31.04% increase year-on-year[6] - Net profit attributable to shareholders decreased by 68.52% to CNY 6,489,569.29 compared to the same period last year[6] - Total operating revenue for Q1 2019 was CNY 80,956,247.28, an increase of 30.96% compared to CNY 61,780,112.64 in Q1 2018[29] - Net profit for Q1 2019 was CNY 2,138,649.36, down 87.84% from CNY 17,526,158.26 in Q1 2018[31] - The profit attributable to shareholders of the parent company decreased to CNY 6,489,569.29, a decline of 68.42% compared to CNY 20,614,166.42 in the previous year[31] - Total profit for Q1 2019 was CNY 1,005,453.99, a decrease of 94.86% from CNY 19,534,897.82 in Q1 2018[29] - The total comprehensive income for Q1 2019 was CNY 2,138,649.36, a decrease of 87.84% from CNY 17,526,158.26 in Q1 2018[31] Cash Flow - Net cash flow from operating activities surged by 210.67% to CNY 3,741,411.96 compared to the previous year[6] - The net cash flow from operating activities for Q1 2019 was ¥3,741,411.96, compared to ¥1,204,316.89 in Q1 2018, indicating an increase of about 210.5%[39] - The cash inflow from sales and services reached ¥66,359,239.06, a significant increase from ¥40,681,805.60 in Q1 2018, representing a growth of approximately 63.2%[38] - The total cash outflow from operating activities in Q1 2019 was ¥83,100,591.39, compared to ¥41,535,654.75 in Q1 2018, an increase of about 99.8%[39] - The cash flow from financing activities in Q1 2019 was ¥6,401,875.00, down from ¥15,468,213.70 in Q1 2018, a decrease of approximately 58.7%[40] Assets and Liabilities - Total assets increased by 0.19% to CNY 1,751,841,491.28 compared to the end of the previous year[6] - The company reported a total current asset of approximately RMB 783.81 million as of March 31, 2019, compared to RMB 787.47 million at the end of 2018[23] - Total liabilities stood at CNY 723,942,927.27, slightly up from CNY 722,814,499.85, representing a marginal increase of 0.16%[25] - Current liabilities decreased to CNY 656,258,689.49 from CNY 657,313,262.07, indicating a reduction of about 0.16%[24] - Shareholders' equity totaled CNY 1,027,898,564.01, an increase from CNY 1,025,759,914.65, showing a growth of approximately 0.21%[25] Research and Development - Research and development expenses rose by 135.27% to CNY 8,714,031.34 due to an increase in the scope of consolidation[12] - Research and development expenses increased significantly to CNY 8,714,031.34, a 134.06% rise from CNY 3,703,777.96 in Q1 2018[29] - Shanghai Jiemen Biotechnology Co., a wholly-owned subsidiary, achieved continuous growth in all financial indicators and exceeded performance targets, increasing R&D spending on future star products[15] - The company plans to continue focusing on self-research and production to provide cost-effective in vitro diagnostic products and services[15] Shareholder Information - The number of shareholders reached 18,554, with the largest shareholder holding 50.90% of the shares[11] Investment Income - Investment income decreased by 41.84% to CNY 5,334,469.61, primarily due to reduced financial investment returns[12] - The company experienced a net investment income of CNY 5,334,469.61, down 41.73% from CNY 9,172,705.58 in Q1 2018[29] Inventory and Accounts Receivable - The company reported a significant increase of 38.76% in accounts receivable, totaling CNY 83,331,819.37, attributed to increased government procurement sales[12] - Accounts receivable increased from RMB 60.05 million at the end of 2018 to RMB 83.33 million as of March 31, 2019[23] - Inventory decreased from RMB 128.76 million at the end of 2018 to RMB 115.90 million as of March 31, 2019[23] - Inventory decreased to CNY 52,042,408.31 from CNY 56,733,250.79, indicating a decline of about 8.25%[27] Regulatory and Compliance - The company executed a new financial instrument standard starting January 1, 2019, affecting the financial statement format[48] - The financial statement format has been revised according to the Ministry of Finance's notification[52] - There are no adjustments for the new financial instrument and leasing standards applicable for prior comparative data[53] - The audit report is not applicable for this period[53] - The company has not reported any treasury stock[52]